Janssen Signs a Worldwide Collaboration with Fate Therapeutics for Novel iPSC-Derived Cell-Based Cancer Immunotherapies
Shots:
- Fate to receive $50M up front and $50M equity investment at $31/ share and funding for the research and development of collaboration candidates through IND filing. The company will receive up to $1.8B as development & regulatory milestones and up to $1.2B as a commercial milestone along with royalties on global sales of products targeting the antigens
- The collaboration leverages Fate’s iPSC to develop iPSC-derived CAR NK and CAR T-cell therapies while Janssen will provide its antigen-binding domains for up to four tumor-associated antigen targets for hematologic malignancies and solid tumors
- Fate will advance the candidates up to IND filing- after which Janssen has the right to exercise its option to develop & commercialize the candidates. Additionally- Fate has the right to co-commercialize each candidate with an equal share in profits and losses in the US
Click here to read full press release/ article
Ref: Fate therapeutics | Image: Janssen
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com